サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1542953

創傷洗浄システムの世界市場：2024年～2031年

Global Wound Irrigation System Market - 2024-2031

出版日
ページ情報
英文 181 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.08円
創傷洗浄システムの世界市場：2024年～2031年
出版日: 2024年08月26日
発行: DataM Intelligence
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

レポート概要

創傷洗浄システムの世界市場は、2023年に2億8,300万米ドルに達し、2031年には3億7,295万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは3.6%で成長する見込みです。

創傷洗浄システムとは、微生物のコロニー形成を抑制し、見かけ上の異物や創傷滲出液を除去するために、露出した創傷表面に溶液を流すことです。創傷潅注（創傷閉鎖前に創傷を洗浄すること）は、創傷閉鎖前に手術野から組織残屑、代謝廃棄物、組織滲出液を除去することにより、微生物負担を軽減することを目的としています。創傷洗浄が正しく行われれば、治癒が早まり、合併症のリスクも軽減されます。

洗浄を避けるべき創傷は、出血が活発な創傷のみです。洗浄の主な利点は、洗浄に適した健康的な湿潤環境を保ち、デブリードマンを助け、創傷治癒プロセスを改善することです。正しく行えば、創傷の治癒にかかる時間を短縮し、瘢痕を最小限に抑えることができます。創傷洗浄は非常に簡単なので、創傷の場所に関係なく、どこにいても簡単に行うことができます。

市場力学：

促進要因

慢性創傷の増加

世界の創傷洗浄システム市場の需要は、複数の要因によって牽引されています。慢性創傷の有病率の上昇が市場成長を促進します。

さらに、この市場の需要は、最近の外科手術の増加によって促進されます。創傷洗浄システムは、様々な外科手術において非常に重要な役割を果たしています。また、60歳以上の高齢者人口の増加も市場を牽引する要因の一つです。この分野における技術の進歩も、創傷洗浄システム市場を牽引する大きな要因の一つです。

慢性創傷とは、正常で整然としたタイムリーな一連の修復過程を経て進行しない創傷のことです。例えば、Wounds Internationalが掲載した記事によると、ある推計によると2023年12月には、7,700万人の糖尿病患者のうち25％が糖尿病性足潰瘍を発症するといいます。静脈性潰瘍は下肢の慢性静脈不全の最も重篤で衰弱させる結果であり、下肢潰瘍の80％を占める。インドにおける慢性創傷の有病率は、人口1,000人当たり4.5人と推定されています。

facs.orgによると、先進諸国では人口の1～2％が生涯に慢性創傷を患うと推定されています。国際糖尿病連合によると、世界の成人人口（20～79歳）の10.5％が糖尿病であると推定されているが、その半数近くは糖尿病に気づいていないです。

抑制要因

高度な創傷システムに関連する高コスト、新興国市場での限定的な利用可能性、感染による危険性などの要因が市場の妨げになると予想されます。

市場セグメンテーション

世界の創傷洗浄システム市場は、製品タイプ、用途、エンドユーザー、地域によって区分されます。

慢性創傷セグメントは、創傷洗浄システムの世界市場シェアの約44.1%を占めています。

慢性創傷セグメントは予測期間中最大の市場シェアを占めると予想されます。このセグメントでは、政府規制の開拓、慢性創傷洗浄の技術進歩がこの市場を牽引すると思われます。

世界人口の慢性疾患の増加により、慢性創傷は近年増加しています。nih.govによると、静脈性下腿潰瘍は慢性静脈不全（CVI）と静脈性高血圧の結果であり、臨床上の大きな課題です。3ヵ月後の治癒率は40％と推定され、一旦治癒しても80％の患者が3ヵ月以内に再発します。VLUの有病率は約1.08％、発症率は1.33％と報告されています。VLUの有病率と発生率は年齢とともに増加します。

褥瘡は、圧迫、または圧迫とせん断の組み合わせにより、通常骨隆起の上に生じる皮膚および/または下層組織の局所的損傷です。米国では約250万件の入院が褥瘡によるものと推定されています。英国では、総治療費の4％が褥瘡治療に充てられています。褥瘡の治療に費やされる余分な費用に加え、入院に伴うベッドの予約や関連費用が発生します。また、褥瘡は看護スタッフの仕事量を50%増加させます。

市場地域別シェア

創傷洗浄システムの世界市場シェアは北米が約46.3％を占める

予測期間中、北米地域が最大の市場シェアを占めると予想されます。慢性創傷の罹患率の上昇、人々の意識の高まり、この地域の政府から割り当てられた資金が市場を後押ししています。

facs.orgによると、米国では慢性創傷が約650万人の患者に影響を与えていると報告されています。米国政府は創傷治療に関して非常に多額の資金を割り当てています。慢性創傷が社会に与える経済的負担は相当なものです。米国では、創傷に関連した合併症の治療に年間250億米ドル以上がヘルスケアシステムによって費やされています。慢性創傷は米国総人口の約2.5％のQOLに影響を与えています。この割合は高齢者ほど大きいです。これらの創傷は様々な合併症やヘルスケアコストにつながります。

北米地域における技術の進歩が、市場シェア最大の理由のひとつです。米国メディケア・メディケイドサービスセンターは、糖尿病性足潰瘍および静脈性下腿潰瘍の治療に皮膚代用移植片／細胞および／または組織ベースの製品の使用を制限する地域適用範囲決定の改訂を米国メディケア集団に提案していました。

米国食品医薬品局（FDA）は、非治癒性慢性創傷への対応に改めて重点を置き、非治癒性慢性創傷に対する製品開発の障壁に対処するための取り組みを概説しました。この新しいアプローチでは、学術界、専門家団体、患者団体、保険償還団体、産業界など、創傷治癒に関わる主要な利害関係者を巻き込むことを重視しています。最後に、現在のFDAの創傷閉鎖の定義では、バリア機能の回復が不十分なために創傷が機能的に開いたままになる可能性があることを示す最近の進歩は、創傷閉鎖のエンドポイントを再検討することを正当化しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 慢性創傷の増加
      • 外科手術の増加
      • 高齢者人口の増加
      • 技術の進歩
  • 抑制要因
    • 高度な創傷洗浄システムの高コスト
    • 発展途上地域での限られたアクセシビリティ
  • 機会
  • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ
  • PESTEL分析
  • 特許分析
  • SWOT分析

第6章 製品タイプ別

  • 手動式
  • 電池式

第7章 用途別

  • 急性創傷
  • 慢性創傷
  • その他

第8章 エンドユーザー別

  • 病院
  • 外来手術センター
  • 在宅医療
  • 学術研究センター
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • Zimmer Biomet
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Striker Corporation
  • Bionix Llc.
  • Irrimax Corporation
  • Cooper Surgical Inc.
  • Westmed Inc.
  • Becton Dickson and Company
  • Essity Health & Medical
  • Centurion Service Group
  • Hopkins Medical Products（*LIST NOT EXHAUSTIVE）

第12章 付録

目次
Product Code: MD4319

Report Overview

The Global Wound Irrigation System Market reached US$ 283 million in 2023 and is expected to reach US$ 372.95 million by 2031, growing at a CAGR of 3.6% during the forecast period 2024-2031.

A Wound Irrigation system is described as the flow of a solution through an exposed fracture surface to reduce microbial colonization, to remove apparent foreign particles and wound exudates. Wound irrigation, that is washing out a wound before wound closure) aims to reduce the microbial burden by removing tissue debris, metabolic waste, and tissue exudate from the surgical field before site closure. When wound irrigation is done correctly, it speeds up the healing process and reduces the risk of complications.

The only types of wounds that you should avoid irrigating are those that are actively bleeding. The primary advantages of irrigation are that it helps keep a healthy, moist environment that's conducive to cleaning, assists debridement, and improves the wound healing process. When done correctly, it reduces the amount of time a wound takes to heal and can help minimize scarring. Since wound irrigation is fairly straightforward, it's easy to perform anywhere you are, regardless of the location of your wound.

Market Dynamics: Drivers

Increasing prevalence of chronic wounds

The demand for the global wound irrigation system market is driven by multiple factors. The rising prevalence of chronic wounds propels the market growth.

Furthermore, the demand for this market will be fueled by the increase in surgical procedures in recent times. The wound irrigation system plays a very vital role in various surgical procedures. The increase in the population of older people who are 60 years and above is also one of the driving factors. Technological advancements in this field are also one of the major driving factors in the wound irrigation system market.

Chronic wounds are those that do not progress through a normal, orderly, and timely sequence of repair. For instance, according to an article posted by Wounds International, in December 2023, according to one estimate, out of 77 million individuals with diabetes, 25% develop a diabetic foot ulcer. Venous ulcers are the most severe and debilitating outcome of chronic venous insufficiency in the lower limbs, accounting for 80% of lower-extremity ulcerations. The prevalence of chronic wounds in India is estimated to be 4.5 per 1,000 people.

According to facs.org, it is estimated that 1 to 2 percent of the population in developed countries will suffer from a chronic wound in their lifetime. According to the International Diabetes Federation, 10.5% of the adult global population (20 - 79 years) is estimated to have diabetes with almost half of the people being unaware of it.

Restraints

Factors such as high cost associated with advanced wound systems, limited availability in developing countries, and hazards caused due to infection are expected to hamper the market.

Market Segment Analysis

The global wound irrigation system market is segmented based on product type, application, end-user, and region.

The segment chronic wounds accounted for approximately 44.1% of the global wound irrigation system market share

The chronic wounds segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and technological advancements for chronic wound irrigation would drive this market.

Due to the increase in chronic diseases in the global population, there has been an increase in chronic wounds in recent times. According to nih.gov, venous leg ulcers are a major clinical challenge they are the result of chronic venous insufficiency(CVI) and venous hypertension. Their three-month healing rate is estimated at 40 %and once healed up to 80% of patients develop a recurrence within 3 months. The prevalence of VLUs is reported around 1.08% and the incidence is up to 1.33%. The prevalence and incidence of VLU increase with age.

Pressure Ulcer is a localized injury to the skin and/or underlying tissue usually over a bony prominence, as a result of pressure, or pressure in combination with shear. It is estimated that about 2.5 million hospitalizations in the United States are due to pressure ulcers. In the UK, 4% of the total treatment costs are allocated for the treatment of pressure ulcers. In addition to the extra costs spent on the treatment of pressure ulcers, there are bed reservations and associated costs arising from hospitalization. These ulcers also cause the nursing staff an increase in workload by 50%

Market Geographical Share

North America accounted for approximately 46.3% of the global wound irrigation system market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of chronic wounds, growing awareness among people, and the funding allotted by the government in this region help to propel the market.

According to facs.org, In the United States, it is reported that chronic wounds affect approximately 6.5 million patients. The US government allotted a very hefty funding regarding wound care. The financial burden imposed by chronic wounds on society is substantial. In the United States, more than $25 billion is spent by the healthcare system on treating wound-related complications per year. Chronic wounds impact the quality of life of nearly 2.5% of the total population of the United States. This fraction is larger in the elderly. These wounds can lead to a range of complications and healthcare costs.

The technological advancements in the region of North America are one of the reasons for the largest market share. The U.S. Centers for Medicare and Medicaid Services had proposed a revision of its local coverage determination limiting the use of skin substitute grafts/cellular and/or tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers in the U.S. Medicare population.

The U.S. Food and Drug Administration (FDA) has renewed its focus on addressing non-healing chronic wounds and has outlined efforts to address identified barriers to product development for non-healing chronic wounds. The new approach emphasizes engaging key wound-healing stakeholders, including academia, professional associations, patient groups, reimbursement organizations, and industry. Finally, recent advances demonstrating that wounds closed by the current FDA definition of wound closure may remain functionally open because of deficiencies in the restoration of barrier function warrant revisiting the wound closure endpoint.

Market Segmentation

By Product Type

  • Manual Operated
  • Syringe Based
  • Spray Based
  • Nozzle Based
  • Battery Operated

By Application

  • Acute Wounds
  • Surgical Wounds
  • Traumatic Wounds
  • Burnt Wounds
  • Chronic Wounds
  • Diabetic foot Ulcers
  • Venous Ulcers
  • Pressure Ulcers
  • Others

By End-User

  • Hospitals
  • Ambulatory Surgical Centre
  • Homecare
  • Academic and Research Institutes
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
  • Middle East and Africa

Market Competitive Landscape

The major global players in the global wound irrigation system market include Zimmer Biomet, Stryker Corporation, Bionix Llc., Irrimax Corporation, Cooper Surgical Inc., Westmed Inc., Becton Dickson and Company, Essity Health & Medical, Centurion Service Group, and Hopkins Medical Products among others.

Key Developments

  • In June 2021, Irrimax Corporation, manufacturer of irrisept, announced new clearance from the U.S. Food and Drug Administration (FDA), making irrisept the only self-contained irrigation system for antimicrobial wound lavage in the U.S. market. Today, more than 2,000 U.S. hospitals are using the irrisept product totaling more than 2 million lifetime uses.
  • In April 2021, the FDA notified that Zimmer Biomet's single-step application wound irrigation solution, XPERIENCE No Rinse Antimicrobial Solution, has been cleared in the U.S. for immediate distribution. The device was originally submitted to the FDA as MIS Solution but is now being marketed as XPERIENCE.
  • In May 2021, BD (Becton, Dickinson, and Company) a leading global medical technology company, announced today the availability of BD Surgiphor(TM) Sterile Wound Irrigation System, the first and only ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution that mechanically loosens and removes wound debris.

Why Purchase the Report?

  • To visualize the global wound irrigation system market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The global wound irrigation system market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Chronic Wounds
      • 4.1.1.2. Increase in Surgical Procedures
      • 4.1.1.3. Increase in population of older people
      • 4.1.1.4. Technological Advancements
  • 4.2. Restraints
    • 4.2.1. High Cost of Advanced Wound Irrigation Systems
    • 4.2.2. Limited Accessibility in Developing Regions
  • 4.3. Opportunity
  • 4.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Manual Operated*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Battery Operated

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Acute Wounds *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Chronic Wounds
  • 7.4. Others

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Homecare
  • 8.5. Academic and Research Centers
  • 8.6. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Zimmer Biomet *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Striker Corporation
  • 11.3. Bionix Llc.
  • 11.4. Irrimax Corporation
  • 11.5. Cooper Surgical Inc.
  • 11.6. Westmed Inc.
  • 11.7. Becton Dickson and Company
  • 11.8. Essity Health & Medical
  • 11.9. Centurion Service Group
  • 11.10. Hopkins Medical Products (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us